Molecularly guided precision therapy in metastatic adamantinoma: a case report.
증례보고
1/5 보강
Adamantinoma is a rare bone tumor characterized by a propensity for local recurrence and distant metastasis.
APA
Musaelyan AA, Odintsova SV, et al. (2025). Molecularly guided precision therapy in metastatic adamantinoma: a case report.. Personalized medicine, 22(6), 345-350. https://doi.org/10.1080/17410541.2025.2600909
MLA
Musaelyan AA, et al.. "Molecularly guided precision therapy in metastatic adamantinoma: a case report.." Personalized medicine, vol. 22, no. 6, 2025, pp. 345-350.
PMID
41370129 ↗
Abstract 한글 요약
Adamantinoma is a rare bone tumor characterized by a propensity for local recurrence and distant metastasis. Management of metastatic disease remains challenging owing to the absence of standardized therapy and the limited efficacy of conventional chemotherapy. This case report describes a young woman with adamantinoma harboring an XRCC2 frameshift mutation. She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Female
- Adamantinoma
- Precision Medicine
- Phthalazines
- Adult
- Bone Neoplasms
- Bevacizumab
- Piperazines
- Antibodies
- Monoclonal
- Humanized
- Poly(ADP-ribose) Polymerase Inhibitors
- Neoplasm Metastasis
- Frameshift Mutation
- Antineoplastic Combined Chemotherapy Protocols
- PARP inhibitor
- XRCC2
- bevacizumab
- immune checkpoint inhibitor
- olaparib
- personalized therapy
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.